Southcoast Announces 2014 First Quarter Results MT.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Southcoast Announces 2014 First Quarter Results

MT. PLEASANT, S.C., April 10, 2014 (GLOBE NEWSWIRE) -- Southcoast Financial Corporation (Nasdaq: SOCB ) announced that it had unaudited pretax income of $988,000 and after tax net income of $643,000, or $.09 per basic share, for the quarter ended March 31, 2014. This compares to unaudited pretax income of $1,061,000 and after tax net income of $1,006,000, or $0.14 per basic share, for the quarter ended March 31, 2013. The March 31, 2014 income per share is based on 7,085,818 basic average shares compared to 7,070,375 basic average shares for 2013. The 2014 results include the continued improvement in asset quality, deposit mix and net interest margin.

For the quarter ended March 31, 2014, net interest income totaled $3,630,000, an increase of $197,000 from $3,433,000 for the quarter ended March 31, 2013. The net interest margin increased to 3.81% as of March 31, 2014 from 3.65% as of March 31, 2013.

Noninterest income for 2014 decreased to $488,000 from $589,000 for 2013, primarily due to an $83,000 reduction in mortgage loan and related fees.

Noninterest expense levels increased to $3,130,000 for 2014 from $2,961,000 for 2013. Included in 2013 was the benefit of $288,000 in net gains on sales of other real estate owned compared to only $105,000 in 2014.

Tax expense increased to $345,000 for 2014 from $55,000 for 2013. In the first quarter of 2013, the company was not accruing any Federal income tax due to its deferred tax asset (DTA) valuation allowance. The valuation allowance was reversed later in 2013, requiring tax expense to once again be accrued.

Total assets as of March 31, 2014 were $453.0 million compared to $447.4 million as of December 31, 2013, an increase of 1.26%. Loans, excluding loans held for sale, increased 2.23% to $339.3 million, from $331.9 million as of December 31, 2013. Deposits increased by $15.6 million to $331.5 million at March 31, 2014, from $315.8 million at December 31, 2013. This increase was comprised of an $11.9 million increase in noninterest demand deposits and a $5.5 million increase in time deposits, offset by a $1.8 million decrease in interest bearing nontime deposits. Growth in core deposits is a major strategy incorporated into our 2014 strategic plan.

The Company's ratio of nonperforming assets to total assets was 2.92% as of March 31, 2014, compared to 3.90% as of March 31, 2013. The allowance for loan losses as a percentage of loans was 1.81% as of March 31, 2014, compared to 2.41% as of March 31, 2013. The allowance for loan losses as a percentage of total nonperforming loans totaled 68.61% as of March 31, 2014, compared to 74.88% as of March 31, 2013. The year to year reduction in the allowance for loan losses to total loans was reflective of improved credit quality in the loan portfolio, most notably due to a significant reduction in criticized and classified loans. The subsidiary bank's capital position as of March 31, 2014 remains in excess of regulatory well-capitalized requirements.

"We are proud of the improvements in our Company's performance as they reflect the loyalty of our customers and the dedication of our employees," said L. Wayne Pearson, Chairman and Chief Executive Officer.

About Southcoast Financial Corporation

Southcoast Financial Corporation, headquartered in Mt. Pleasant, South Carolina, is the holding company of Southcoast Community Bank. The Bank, which opened for business July 20, 1998, is a state chartered commercial bank operating from its main office at 530 Johnnie Dodds Boulevard in Mt. Pleasant, South Carolina and nine branches in the Charleston, South Carolina area. Southcoast Financial Corporation's common stock is traded on the NASDAQ Global Market under the symbol SOCB.

Southcoast Financial Corporation
Consolidated Balance Sheets
(Dollars in thousands)
 
  March 31 December 31
  2014 2013
  (Unaudited)  
Assets    
Cash and cash equivalents $ 29,280 $ 28,460
Investments 42,908 43,451
Loans held for sale 0 271
Loans 339,291 331,906
Less: Allowance for loan losses 6,146 6,041
     
Net loans 333,145 325,865
Fixed assets 20,950 21,150
Other assets 26,743 28,187
     
Total Assets $ 453,026 $ 447,384
     
Liabilities & Shareholders' Equity    
Deposits:    
Noninterest bearing $ 52,337 $ 40,399
Interest bearing nontime 137,100 138,899
Time deposits 142,024 136,530
     
Total deposits 331,461 315,828
Other borrowings 63,694 73,818
Other liabilities 4,003 4,859
Junior subordinated debentures 10,310 10,310
     
Total liabilities 409,468 404,815
     
Shareholders' Equity    
Common Stock 54,565 54,544
Accumulated deficit  (9,294)  (9,937)
Accumulated other comprehensive loss  (1,713)  (2,038)
     
Total shareholders' equity 43,558 42,569
     
Total Liabilities and Shareholders' equity $ 453,026 $ 447,384
     
Book Value Per Share $ 6.15 $ 6.01
 
Southcoast Financial Corporation
Consolidated Income Statement
(Dollars in thousands, except share data)
 
 
  Quarter Ended
  March 31, March 31,
  2014 2013
  (Unaudited) (Unaudited)
Interest Income    
Interest and fees on loans $ 4,235 $ 4,201
Interest on investments 301 252
Interest on Fed funds sold 6 6
     
Total interest income 4,542 4,459
     
Interest expense 912 1,026
     
Net interest income 3,630 3,433
Provision for loan losses  --  --
     
Net interest after provision 3,630 3,433
     
Noninterest income 488 589
     
Total noninterest income 488 589
     
Total operating income 4,118 4,022
     
Noninterest expense    
Salaries and benefits 1,759 1,679
Occupancy and furniture and equipment 719 753
Other expenses 652 529
     
Total noninterest expense 3,130 2,961
     
Income before taxes 988 1,061
Income tax expense 345 55
     
Net income $ 643 $ 1,006
     
Basic net income per common share $ 0.09 $ 0.14
     
Diluted net income per common share $ 0.09 $ 0.14
     
Average number of common shares    
Basic 7,085,818 7,070,375
Diluted 7,085,818 7,070,375
 
Southcoast Financial Corporation
SELECTED FINANCIAL DATA
(dollars in thousands, except earnings per share)
 
  Three Months Ended
  March 31, 2014 March 31, 2013
  (Unaudited)
INCOME STATEMENT DATA    
Net interest income  $ 3,630  $ 3,433
Provision for loan losses  --   -- 
Noninterest income 488 589
Noninterest expenses 3,130 2,961
Income Tax expense 345 55
Net income  $ 643  $ 1,006
     
PER SHARE DATA    
Net income per share    
Basic  $ 0.09  $ 0.14
Diluted  $ 0.09  $ 0.14
     
     
Average shares outstanding 1    
Basic 7,085,818 7,070,375
Diluted 7,085,818 7,070,375
     
Key ratios    
Return on assets 2 0.59% 0.95%
Return on equity 2 6.06% 11.74%
Nonperforming assets to assets 3 2.92% 3.90%
Reserve to loans 4 1.81% 2.41%
Reserve to nonperforming loans 68.61% 74.88%
Net interest margin 2 3.81% 3.65%

1 Prior period per share amounts adjusted for 15% stock dividend paid during June 2013.

2 Ratios for three months are annualized.

3 Includes nonaccruing loans, loans 90 or more days past due still accruing interest, troubled debt restructures, and other real estate owned.

4 Includes nonaccruing loans, loans 90 or more days past due still accruing interest, and troubled debt restructures.

William C. Heslop Senior Vice President and Chief Financial Officer (843) 216-3019

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 9

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 26

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading

Top 5 Most Recently Viewed Articles

BioSyent Inc. to Announce Q3 Financial Results This Month

Updated Category News Views 189

BioSyent Inc. to Announce Q3 Financial Results BioSyent Inc., a prominent player in the specialty pharmaceutical industry, is preparing to release its financial results for the third quarter and year-to-date period. This important announcement is scheduled for November 20, prior to the market opening. The report will cover the company's performance for the three and nine...

Continue Reading
Dr. Ryan Egeland Joins Solventum as Chief Medical Officer

Updated Category News Views 381

Solventum Welcomes Dr. Ryan Egeland as New CMO Solventum, a pioneering healthcare company, recently announced the appointment of Dr. Ryan Egeland, MD, as their Chief Medical Officer. In this significant role, Dr. Egeland will lead the Global Medical and Clinical Affairs team, amplifying clinician and patient voices within the organization. Fostering Collaboration and...

Continue Reading
MiningToken Revolutionizes Cryptocurrency With AI Power

Updated Category News Views 186

Introducing MiningToken's Innovative AI Cloud Mining Service Bitcoin and Ethereum are experiencing remarkable market dynamics as Bitcoin persists in a bullish trend and Ethereum has gained notable ground recently. As global interest in cryptocurrencies grows, effective mining strategies are crucial for profitability. Amidst rising operational costs, many individuals seek...

Continue Reading
Saluda Medical's EVA™ Sensing Technology Approved in Europe

Updated Category News Views 111

Saluda Medical Achieves Regulatory Milestone with EVA™ Technology Saluda Medical, Inc. (ASX:SLD) has made significant strides in the medical device industry by achieving CE certification for its next-generation EVA™ Sensing Technology. This advancement not only marks a major endorsement in Europe but also is recognized in Australia. Following FDA approval in December...

Continue Reading
ReadPartner Inc. Unveils Revolutionary AI Tool to Combat Misinformation

Updated Category News Views 291

ReadPartner Inc. Launches AI Feature to Tackle Misinformation ReadPartner Inc., a leader in AI-driven media intelligence solutions, is excited to announce the upcoming launch of a groundbreaking digital security feature named ProfileScreen. This innovative tool aims to address the pressing issue of misinformation that plagues social media platforms. The ProfileScreen...

Continue Reading